Inhibition of PI3K as a potential therapeutic approach in UC has not previously been examined, though mutations in PIK3CA represent the most frequent PI3K pathway mutations in this cancer type, including 12–20 % of muscle-invasive tumors [14, 22]. The gene discussed is PIK3CD; the disease is cancer.